Dr. Daniel Alexander Laheru, MD

Dr. Laheru practices at Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland.

Dr. Laheru's NPI, 1497796510, was assigned on June 9, 2006. Dr. Laheru graduated from Baylor College of Medicine in 1995. Dr. Laheru holds Maryland license D53070.

Dr. Laheru's primary practice is Johns Hopkins Hospital Nelson/Harvey Building, at 600 N Wolfe St, Baltimore, MD 21287 in Baltimore City. The practice phone is (855) 662-3017.

Dr. Laheru's primary practice is Johns Hopkins Hospital Nelson/Harvey Building in Baltimore, Maryland. Dr. Laheru is also affiliated with The Johns Hopkins Hospital. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Laheru to 1 more hospital and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Laheru practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Laheru's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Laheru is licensed in Maryland.

CMS data shows 41,731 Medicare services from Dr. Laheru across 21 procedure codes in 2024, for 288 Medicare patients. Medicare paid $127,558 for them.

CMS counts 288 Medicare patients who saw Dr. Laheru in 2024. The largest group is 65 to 74, with 143 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 7% are also on Medicaid. Their average risk score is 2.06, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Laheru's median patient age at 74, with 51% women.

In 2024, Dr. Laheru wrote 134 Medicare Part D claims for 49 patients. 83% of them were for generic drugs. CMS names the drug for 56 of them, across 3 drugs with 11 or more claims each, at $951 in total drug cost. In 2023, CMS named 13 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Laheru for performance year 2024, reported as part of a group. CMS lists Dr. Laheru as offering telehealth.

Dmand AI links 149 papers to Dr. Laheru, published from 2010 to 2025. 2022 was the busiest year, with 10. The most frequent topics are Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal and Antineoplastic Combined Chemotherapy Protocols. Dr. Laheru has published most often in Clin Cancer Res. Dr. Laheru's most frequent co-authors are Lei Zheng, MD, Christopher Wolfgang, MD, PhD and Elizabeth Jaffee, MD.

Dmand AI links Dr. Laheru to 9 clinical trials, 4 of them phase 1 studies. 1 is still active or recruiting. Conditions studied include Pancreatic Neoplasms, Pancreatic Diseases and Carcinoma, Hepatocellular. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sponsors the most, 2.

CMS Open Payments shows 26 general payments to Dr. Laheru from 6 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 68% of the total. Amgen Inc. paid the most, $11,892. It also lists 5 research payments totaling $6,650 from 2020 to 2022.

Dr. Laheru graduated from Baylor College of Medicine in 1995.